brentuximab vedotin (Recombinant) for IV Infusion
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for brentuximab vedotin (Recombinant) for IV Infusion, covering 2019-05-06 to 2019-05-06. Get the full timeline:
Most recent: Clinical Trial Update: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"